Treatment of classical Hodgkin's lymphoma in children and adolescents.

Abstract:

INTRODUCTION:The treatment of classical Hodgkin lymphoma (cHL) in children is a story of success. Nowadays, more than 90% of patients are cured and overall survival is nearly 100% at 5 years. Efforts have been made to avoid related effects of therapies; therefore, children are treated using different chemotherapy schemes in comparison with adults. AREAS COVERED:This review includes a view of the clinical classification and risk assessment in children suffering from HL. The chemotherapy more commonly employed is revisited. The use of PET/CT to evaluate the disease in order to guide therapy is analyzed. New options of chemotherapy and emerging immunotherapy are also included. EXPERT OPINION:In order to make the right treatment choice, a proper initial assessment of risk is mandatory. The choice of therapy in these kinds of patients must be done according to the experience of the team, and also, the cost and logistics related to the eligible scheme are very important. If possible, efforts must be made to include PET/CT in guiding therapy and avoiding overtreatment and long-term adverse effects in children. New options in immunotherapy are emerging and must be considered with caution in selected patients.

authors

Gómez-Almaguer D,González-Llano O,Jiménez-Antolinez V,Gómez-De León A

doi

10.1080/14656566.2019.1606212

subject

Has Abstract

pub_date

2019-07-01 00:00:00

pages

1227-1234

issue

10

eissn

1465-6566

issn

1744-7666

journal_volume

20

pub_type

杂志文章,评审
  • Latest treatment strategies for membranous nephropathy.

    abstract::Thirty to forty percent of patients with idiopathic membranous nephropathy have persistent heavy proteinuria and may progress to end-stage kidney disease in 5 - 15 years. The ideal treatment for these patients is a matter of debate. Several nonspecific immunosuppressive regimens have been suggested with the aim of red...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.18.3159

    authors: Ruggenenti P,Cravedi P,Remuzzi G

    更新日期:2007-12-01 00:00:00

  • Current treatment options and strategies for myelodysplastic syndromes.

    abstract:BACKGROUND:The myelodysplastic syndromes (MDS) are a group of heterogeneous disorders characterized by ineffective hematopoiesis. A number of scoring systems have been developed but they are of limited value in guiding individual patient treatment decisions. OBJECTIVE:We have presented the benefits and limitations of ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.10.1667

    authors: Srinivasan S,Schiffer CA

    更新日期:2008-07-01 00:00:00

  • Irinotecan and bevacizumab in recurrent glioblastoma multiforme.

    abstract:INTRODUCTION:Glioblastoma multiforme (GBM) is the most common high grade primary brain tumor in adults. Despite significant advances in treatment, the prognosis remains poor. Bevacizumab (BVZ) and irinotecan (CPT-11) are currently being investigated in the treatment of GBM patients. Although treatment with BVZ and irin...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.566558

    authors: Jakobsen JN,Hasselbalch B,Stockhausen MT,Lassen U,Poulsen HS

    更新日期:2011-04-01 00:00:00

  • Evolving simplified treatment strategies for HIV infection: the role of a single-class quadruple-nucleoside/nucleotide regimen of trizivir and tenofovir.

    abstract::Simplified antiretroviral regimens have been developed with the aim of improving treatment adherence and quality of life of HIV-infected patients. The single-class triple-nucleoside reverse transcriptase inhibitor combination has contributed to the improvement of the management of HIV infection, especially in patients...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.16.2233

    authors: Mastroianni CM,d'Ettorre G,Vullo V

    更新日期:2006-11-01 00:00:00

  • New antiviral agents for the treatment of hepatitis C: ABT-450.

    abstract:INTRODUCTION:Hepatitis C virus (HCV) therapy continues to evolve rapidly. ABT-450 is a novel potent inhibitor of the non-structural 3/4A protease that has been studied in combination with several agents, allowing shorter duration of therapy and interferon-free/ribavirin-free all-oral regimens. Preliminary data from stu...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.889116

    authors: Carrion AF,Gutierrez J,Martin P

    更新日期:2014-04-01 00:00:00

  • Current understanding of the role of bosentan in inoperable chronic thromboembolic pulmonary hypertension.

    abstract::Chronic thromboembolic pulmonary hypertension may occur in the context of incomplete lysis of acute pulmonary emboli, resulting in the obstruction of pulmonary blood flow, as well as progressive right ventricular dysfunction and failure. The treatment of choice for this condition is surgical removal of the obstructing...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.9.1133

    authors: Hughes R,Jais X,Suntharalingam J,Humbert M,Parent F,Simonneau G,Pepke-Zaba J

    更新日期:2006-06-01 00:00:00

  • Antimicrobial treatment of anaerobic infections.

    abstract:INTRODUCTION:Anaerobes are the most predominant components of normal human skin and mucous membrane bacterial flora and are, therefore, a common cause of endogenous bacterial infections. Because of their fastidious nature, they are difficult to isolate from infectious sites and are often overlooked. Anaerobic infection...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.576672

    authors: Brook I

    更新日期:2011-08-01 00:00:00

  • Desvenlafaxine in the treatment of major depressive disorder.

    abstract::Desvenlafaxine (DESV) is a newer antidepressant, which inhibits serotonin-norepinephrine reuptake neurotransmission, similarly to venlafaxine, milnacipran and duloxetine. It was approved in February 2008 by the FDA for the treatment of major depressive disorder (MDD), based on well-controlled and adequately powered, l...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.636033

    authors: Pae CU

    更新日期:2011-12-01 00:00:00

  • Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary.

    abstract::Peglyated liposomal doxorubicin was developed to maintain or enhance the demonstrated antineoplastic effects of doxorubicin, while improving the toxicity profile associated with this important cytotoxic agent. Accumulating clinical data have confirmed the activity of pegylated liposomal doxorubicin in cancers of the b...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656566.7.11.1469

    authors: Markman M

    更新日期:2006-08-01 00:00:00

  • The value of irbesartan in the management of hypertension.

    abstract::Elevated blood pressure levels are highly prevalent and are a major reason for cardiovascular events and thus place a significant financial burden on healthcare systems worldwide. Guidelines recommend five first-line anti-hypertensive drug classes, but compelling indications may indicate favoring one drug class over a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903103820

    authors: Bramlage P,Durand-Zaleski I,Desai N,Pirk O,Hacker C

    更新日期:2009-08-01 00:00:00

  • Event reduction: revisiting why we treat with statins and harnessing current evidence towards optimal therapy.

    abstract:IMPORTANCE OF THE FIELD:Statins are widely accepted as the drugs of choice for achieving increasingly stringent low-density lipoprotein cholesterol (LDL-C) goals for dyslipidemic patients. However, when making treatment decisions, outcomes data from clinical trials are of greater importance than LDL-C-lowering ability....

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2010.516747

    authors: Weart CW,Hogan RJ

    更新日期:2011-01-01 00:00:00

  • Fidaxomicin for treatment of clostridium difficile-associated diarrhea and its potential role for prophylaxis.

    abstract:INTRODUCTION:Clostridium difficile has become the most important healthcare-associated infection worldwide within the past decade. This is in part due to the emergence of a highly virulent epidemic strain of C. difficile as well as the relative ineffectiveness of current therapies at producing a sustained response. Fid...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.802307

    authors: Hostler CJ,Chen LF

    更新日期:2013-08-01 00:00:00

  • Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C.

    abstract:INTRODUCTION:Chronic hepatitis C infection is a global disease with 160 million people infected worldwide. Until recently, therapy was characterized by long duration, suboptimal success rates and significant adverse drug reactions. The development of direct-acting antivirals initiated a dramatic change in the treatment...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.972364

    authors: Stirnimann G

    更新日期:2014-12-01 00:00:00

  • Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects.

    abstract:INTRODUCTION:Benign prostate hyperplasia (BPH) is one of the most prevalent diseases in aging men. It may adversely affect quality-of-life due to the presence of low urinary tract symptoms (LUTS) and its effects on sexuality. AREAS COVERED:The impact of α1-blockers, 5α-reductase inhibitors (5-ARI), and phosphodiestera...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2020.1817382

    authors: La Vignera S,Aversa A,Cannarella R,Condorelli RA,Duca Y,Russo GI,Calogero AE

    更新日期:2020-09-09 00:00:00

  • The optimal combination therapy for the treatment of early rheumatoid arthritis.

    abstract:INTRODUCTION:Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune condition traditionally viewed as a severe destructive disease affecting physical health and global wellbeing. The treatment strategies for RA have changed in the last decades from mainly symptomatic towards a more vigorous and targeted approac...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1056735

    authors: De Cock D,Van der Elst K,Meyfroidt S,Verschueren P,Westhovens R

    更新日期:2015-01-01 00:00:00

  • Abatacept: a novel treatment for rheumatoid arthritis.

    abstract::Rheumatoid arthritis (RA) is a chronic, autoimmune disease that has traditionally been treated with non-biologic and biologic disease-modifying antirheumatic drugs (DMARDs). Although these agents have become firmly established as effective RA treatments, some patients do not have an adequate response. The recent appro...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.14.2371

    authors: Lundquist LM

    更新日期:2007-10-01 00:00:00

  • Economic evaluations of chronic obstructive pulmonary disease pharmacotherapy: how well are the real-world issues of medication adherence, comorbidities and adverse drug-reactions addressed?

    abstract:INTRODUCTION:When estimating the cost-effectiveness or budget impact of chronic obstructive pulmonary disease (COPD) medication, it is common practice to use trial data for clinical inputs. However, such inputs do not always reflect the real-world situation. Previous reviews recognized the need for taking real-world da...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2021.1873953

    authors: Fens T,Zhou G,Postma MJ,van Puijenbroek EP,van Boven JFM

    更新日期:2021-01-13 00:00:00

  • Pharmacological treatment for insomnia in patients with major depressive disorder.

    abstract:INTRODUCTION:Insomnia in Major Depressive Disorder (MDD) is highly prevalent and associated with increased suffering and functional impairment. Effective, evidence-based treatments for insomnia in MDD are an unmet need in clinical practice. AREAS COVERED:Herein, the authors provide a review of the clinical correlates,...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1614562

    authors: Brietzke E,Vazquez GH,Kang MJY,Soares CN

    更新日期:2019-08-01 00:00:00

  • Delaying surgery with chemotherapy for osteosarcoma of the extremities.

    abstract::Osteosarcoma is the most frequent primary cancer of bone. When treated by surgery alone, it is almost invariably followed by metastatic dissemination and death. This dismal prognosis can be improved dramatically by including chemotherapy in an interdisciplinary regimen. Today, two-thirds of patients with localised ext...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.6.1243

    authors: Bielack SS,Machatschek JN,Flege S,Jürgens H

    更新日期:2004-06-01 00:00:00

  • Current approaches to therapy for vascular injury.

    abstract::Vascular injury is a ubiquitous phenomenon which can be both occult (such as with hyperlipidemia) and overt (such as with angioplasty). While the exact pathophysiology differs between acute and chronic atherosclerosis, both lesions can be mechanistically explained by the vasculature's exaggerated response to injury. P...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.5.753

    authors: Selzman CH

    更新日期:2001-05-01 00:00:00

  • Is long-term adjuvant treatment of breast cancer with anastrozole indicated?

    abstract:BACKGROUND:Tamoxifen is the established adjuvant treatment for postmenopausal women with hormone-sensitive breast cancer. OBJECTIVE:To determine whether the aromatase inhibitor anastrozole should replace tamoxifen as the adjuvant treatment in this cancer. METHODS:Two recent trials of anastrozole and tamoxifen as adju...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656566.9.9.1619

    authors: Doggrell SA

    更新日期:2008-06-01 00:00:00

  • Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer.

    abstract:INTRODUCTION:Breast cancer (BC) remains the most frequently diagnosed cancer and the most common cause of cancer death among women of all races worldwide. Over 80% of BC cases are hormone receptor (HR)-positive, comprised of luminal A and luminal B per molecular subtypes, imposing an urgent need to fully understand the...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2018.1429407

    authors: Duso BA,Trapani D,Viale G,Criscitiello C,D'Amico P,Belli C,Mazzarella L,Locatelli M,Minchella I,Curigliano G

    更新日期:2018-02-01 00:00:00

  • Pharmacotherapeutic strategies for treating hypertension in patients with obesity.

    abstract:INTRODUCTION:Hypertension and obesity are important health challenges that independently increase cardiovascular morbidity and mortality. There is a lack of randomized controlled trials to clearly inform on preferred drug choices to be adopted in clinical practice for the treatment of obesity-related hypertension (OHT)...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1458092

    authors: Carnagarin R,Matthews V,Gregory C,Schlaich MP

    更新日期:2018-05-01 00:00:00

  • Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review.

    abstract:INTRODUCTION:Postprandial hyperglycemia (PPHG) contributes to micro- and macro-vascular complications more than fasting hyperglycemia in patients with type 2 diabetes mellitus. Due to the traditional carbohydrate-rich diet, Asians, particularly Indians and Chinese need agents to control the higher risk of uncontrolled ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1070827

    authors: Joshi SR,Standl E,Tong N,Shah P,Kalra S,Rathod R

    更新日期:2015-01-01 00:00:00

  • Pharmacotherapy of large B-cell lymphoma.

    abstract:BACKGROUND:Constituting approximately 30% of lymphoid malignancies, diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma in adults worldwide. The clinical and biologic heterogeneity that exists in DLBCL suggests that this entity might actually be comprised of several distinct neoplasms that coul...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.13.2247

    authors: Escalón MP,Lossos IS

    更新日期:2008-09-01 00:00:00

  • Ruboxistaurin: PKC-beta inhibition for complications of diabetes.

    abstract::Diabetes mellitus is the most common cause of blindness among working-age adults, with a prevalence of 7 - 8% of adults in the USA, and is one of the most common causes of renal failure requiring kidney transplant and the most common cause of non-traumatic lower limb amputation in developed nations [1] . The role of t...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903401620

    authors: Danis RP,Sheetz MJ

    更新日期:2009-12-01 00:00:00

  • The contentious nature of gestational diabetes: diet, insulin, glyburide and metformin.

    abstract::Gestational diabetes (GD) develops because pregnancy increases requirements for insulin secretion while increasing insulin resistance. Women with GD often have impaired pancreatic beta-cell compensation for insulin resistance. The nature of GD is currently contentious, with debate about its existence, diagnosis and ra...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.3.11.1557

    authors: Glueck CJ,Goldenberg N,Streicher P,Wang P

    更新日期:2002-11-01 00:00:00

  • Etravirine for the treatment of HIV/AIDS.

    abstract:INTRODUCTION:Etravirine (TMC125) is an orally administered second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) that is approved in treatment-experienced patients as addition to an optimized background therapy (OBT). AREAS COVERED:A Medline search was conducted of Phase II - IV clinical trials, as ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.787411

    authors: Schrijvers R

    更新日期:2013-06-01 00:00:00

  • Docetaxel in ovarian cancer.

    abstract::Docetaxel, a semisynthetic taxane, is a potent inhibitor of cell replication and, similar to paclitaxel, promotes in vitro assembly of stable microtubules and, therefore, prevents the depolymerisation process. Docetaxel has a higher affinity for the tubulin subunit and is associated with a 100-fold greater phosphoryla...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.15.2719

    authors: Escobar PF,Rose PG

    更新日期:2005-12-01 00:00:00

  • New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin.

    abstract:BACKGROUND:Sitagliptin is a highly selective oral dipeptidyl peptidase-4 inhibitor. This drug increases the plasma concentration of active glucagon like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide. These two hormones then simulate the secretion of insulin in a glucose-dependent manner and inhibit glu...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.9.1495

    authors: Gagliardino JJ,Santoro S,Arellano S,Di Girolamo G

    更新日期:2008-06-01 00:00:00